Home

The Korea Herald

Latest news

Most Popular

  1. 1

    1 in 3 Koreans live alone, family types becoming diverse

    1 in 3 Koreans live alone, family types becoming diverse
  2. 2

    Korea, Japan finance chiefs vow to tame rampant FX market volatility

    Korea, Japan finance chiefs vow to tame rampant FX market volatility
  3. 3

    US 'incredibly concerned' about suspected NK-Iran military ties

    US 'incredibly concerned' about suspected NK-Iran military ties
  4. 4

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  5. 5

    K-pop singer lost consciousness after being hit by foul ball, cancels show

    K-pop singer lost consciousness after being hit by foul ball, cancels show
  1. 6

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
  2. 7

    Why is Apple Pay struggling to get purchase in Korea?

    Why is Apple Pay struggling to get purchase in Korea?
  3. 8

    Yoon's office denies considering liberal figures for key posts

    Yoon's office denies considering liberal figures for key posts
  4. 9

    Seoul says Fu Bao loan 'not going to happen'

    Seoul says Fu Bao loan 'not going to happen'
  5. 10

    [Today’s K-pop] BTS pop-up event to come to Seoul

    [Today’s K-pop] BTS pop-up event to come to Seoul
소아쌤

Celltrion’s Remicade biosimilar nearing U.S. approval

By Sohn Ji-young

Published : Jan. 18, 2016 - 12:04

    • Link copied

Celltrion is drawing closer to launching its rheumatoid treatment Remsima in the U.S.

The company said Monday that the U.S. Food and Drug Administration is scheduled to hold a committee meeting Feb. 9 (local time) to review and discuss Remsima’s approval in the North American market.

Remsima is a biosimilar replication of Johnson & Johnson’s blockbuster rheumatoid arthritis treatment Remicade.

The entrance to Celltrion's headquarters in Incheon (Yonhap) The entrance to Celltrion's headquarters in Incheon (Yonhap)

The news prompted Celltrion shares to surge by 17.64 percent from the previous trading day, to close at 116,700 won on the secondary Korean bourse on Monday.

The meeting’s outcome will be significant since a positive recommendation from the committee is typically followed by legal approval by the U.S. FDA.

“Given that Remsima has already been approved in 67 countries including those in Europe, the biosimilar drug is expected to be approved in the U.S. as well,” said NH Investment & Securities analyst Lee Seung-ho.

Celltrion’s new drug is set to emerge as a new game changer in the U.S. arthritis treatment market, which takes up roughly 54.5 percent of Remicade’s entire sales globally.

As Remsima clinically proves its ability to treat additional symptoms including those related to inflammatory diseases, its original replacement rate is slated to further increase, raising Celltrion’s stock price in the process, according to Lee.

By Sohn Ji-young (jys@heraldcorp.com)

More from Headlines